Founder of Endpoints News: Daily blast of biotech business news. 17 yrs of context. 54,000+ subscribers. https://t.co/QBiXz8A3RX firstname.lastname@example.org
#3 GSK’s ‘breakthrough’ BCMA cancer drug gets a priority review — and a big win for the oncology R&D team $GSK
Oh, cool. Hit the 70,000 mark on overall subscribers just now. Plan is to hit 80,000 by the 4th anniversary of the launch June 20. Spread the word! We're heading to 100K
I'm watching the latest Terminator movie, which is a bit of a retread, and there's a scene when our hero goes into a pharmacy asking for meds. Pharmacist asks for a dr.'s rx, which is a hoot. You don't need one in Mexico, guys. You pay, you get
Is this the new #FDA safety controversy people have been waiting for? The fallout could be far and wide.
Anybody get riled up seeing a top FDA official lambast a company for selling or attempting to sell dangerous drugs with small -- at best -- efficacy? Who then gets reversed by presumably Janet woodcock? $SRPT
Ionis, Akcea boosted by a positive PhII for their Novartis castoff cardio drug -- and they plan to push ahead into pivotals $IONS $AKCA +17%
An absolute must-read for anyone even vaguely interested in antibiotic development -- this is reality: Biopharma has abandoned antibiotic development. Here’s why we did, too.
Does anyone at this stage believe that paying more in the US gets you better care? This Canada/US comparison seems obvious to me. What I'm saying: disjointed, dysfunctional system with rampant overcharging, opaque pricing leads to-the US healthcare system
I truly hope you spend some time with this one -- Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top
Almost half of all new drug approvals in 2018 relied on one clinical trial @ZacharyBrennan